Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VISIBLE: Guselkumab in Skin of Color Participants with Moderate-to-Severe Plaque or Scalp Psoriasis
NCT05272150Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2022
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of guselkumab in plaque psoriasis and psoriasis (2 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Investigator's Global Assessment Score of Cleared (0) or Minimal (1) at 16 weeks, Psoriasis Area Severity Index 90 Response at 16 weeks and 2 more. Started Jul 2022; status: completed.
02
Drugs
guselkumab
03
Conditions
plaque psoriasispsoriasis
Beyond the preview
Go deeper on NCT05272150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05272150.